Pharmaceuticals company Sun Pharma Advanced Research Company announced Q3FY26 results Consolidated Revenue stood at Rs 845 lakh (down 43% YoY). Consolidated expenses fell 19% YoY to Rs 7,644 lakh; employee costs were higher than the stand-alone level at Rs 3,118 lakh because of subsidiaries. Consolidated loss before exceptional items and tax was Rs 6,799 lakh (Q3FY25: loss Rs 7,944 lakh). Consolidated loss after tax reached Rs 8,042 lakh (Q3FY25 loss Rs 7,951 lakh). Consolidated basic & diluted EPS -Rs 2.48 (Q3FY25 -Rs 2.45). Result PDF
Conference Call with Sun Pharma Advanced Research Company Ltd. Management and Analysts. Listen to the full earnings transcript.